Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphomaOlalekan O. Oluwole, Tom van Meerten, Krimo Bouabdallah et al.|British Journal of Haematology|2021Cited by 217
Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)Caron A. Jacobson, Sattva S. Neelapu, Frederick L. Locke et al.|Blood|2020Cited by 52
Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)Olalekan O. Oluwole, Tom van Meerten, Krimo Bouabdallah et al.|Transplantation and Cellular Therapy|2021Cited by 7
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.Sandro Pignata, Andrew R. Clamp, Margarita Romeo et al.|Journal of Clinical Oncology|2022Cited by 5
Abstract CT166: Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel)Justin A. Budka, Adrian Bot, Justin Chou et al.|Cancer Research|2021Cited by 2